Trial Profile
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 25 Mar 2013 Planned end date changed from 1 Mar 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 27 Jul 2011 Actual initiation date (March 2011) added as reported by ClinicalTrials.gov.
- 27 Jul 2011 Planned End Date changed from 1 Nov 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.